This University of Washington/Fred Hutchinson Cancer Research Center CFAR proposal includes nine funded and six non-funded CFAR Cores. OAR lists 166 AIDS awards for over $36,000,000 to the UW & FHCRC. Funded Cores included A) Administration, providing financial administration and personnel management for approximately $14,000,000 in grants and contracts and 107 CFAR-affiliated staff, faculty and fellows; coordinates facilities and communications, administers a large charge-back cost center for computer graphics and slides (annual budget $160,000) and organizes Advisory Committee meetings. B) Developmental, which has funded 16 new investigators (9 have obtained grants, all continue in AIDS research); and will be enlarged to fund NIAs, and Emerging Opportunity Grants, and sponsor a CFAR Seminar Series. C) Biostatistics, providing the nucleus for coordination of a large UW HIV/AIDS biostatistics research effort, will strengthen support for behavioral and prevention research (and fund a behavioral prevention seminar series), as well as for health services and international research. D) Clinical Research, which previously initiated a primary infection clinic leading to a new NIH Acute Infections & Early Detection Network Award, and funded projects leading to two proposed cores; will continue support of clinical research infrastructure as well as pilot grants for clinical research. E) International began as a subcore of the CRC, and as a new Core will provide stable infrastructure support and fund research for emerging opportunities for many existing UW AIDS clinical and prevention projects in 11 developing countries, as well as for future sites. E) Health Services Research replaces the former AIDS Registry, shifting emphasis from cross-sectional epidemiology to prospective study of critical problems in health care delivery and outcomes research. G) Clinical Retrovirology already over subscribed will expand BL-3 space and introduce new technologies to meet steadily growing research demands. H) The new Molecular Diversity Core has attracted investigators locally and from throughout the US and other countries, introducing new genetic technologies and computational tools for viral sequencing and analysis. I) Molecular Immunology- at the forefront of development of methods for analyzing the cellular immune response - will introduce a peptide synthesis facility; a BL-3 flow cytometry/cell-sorting subcore; a humoral immunity subcore and a monoclonal antibody facility. All cores have oversight Core Committees, and most have core coordinator positions for supervision, and increased outreach. Nine new unfunded auxiliary CFAR cores include the Primate Center; General CRC; ACTU; AVEU; Primary Infection Clinic; Needle Exchange Evaluation Cohort, cohort of HIV sero-positive MSM in Seattle; and cohorts in Senegal & Kenya.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-12
Application #
2882154
Study Section
Special Emphasis Panel (ZAI1-SCO-A (J1))
Program Officer
Plaeger, Susan F
Project Start
1988-09-30
Project End
2003-02-28
Budget Start
1999-03-01
Budget End
2000-02-29
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Wagner, Anjuli D; O?Malley, Gabrielle; Firdawsi, Olivia et al. (2018) Brief Report: Disclosure, Consent, Opportunity Costs, and Inaccurate Risk Assessment Deter Pediatric HIV Testing: A Mixed-Methods Study. J Acquir Immune Defic Syndr 77:393-399
Golovaty, Ilya; Sharma, Monisha; Van Heerden, Alastair et al. (2018) Cost of Integrating Noncommunicable Disease Screening Into Home-Based HIV Testing and Counseling in South Africa. J Acquir Immune Defic Syndr 78:522-526
LaCourse, Sylvia M; Cranmer, Lisa M; Njuguna, Irene N et al. (2018) Urine Tuberculosis Lipoarabinomannan Predicts Mortality in Hospitalized Human Immunodeficiency Virus-Infected Children. Clin Infect Dis 66:1798-1801
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Ross, Jennifer M; Ying, Roger; Celum, Connie L et al. (2018) Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. Epidemics 23:34-41
Patel, Rena C; Bukusi, Elizabeth A; Baeten, Jared M (2018) Current and future contraceptive options for women living with HIV. Expert Opin Pharmacother 19:1-12
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537
Wagner, Anjuli D; Shah, Seema K; Njuguna, Irene N et al. (2018) Financial Incentives to Motivate Pediatric HIV Testing-Assessing the Potential for Coercion, Inducement, and Voluntariness. J Acquir Immune Defic Syndr 78:e15-e18

Showing the most recent 10 out of 1275 publications